A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 227 participants.
Also called NCT06716203
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 227 participants
- Registry
-
NCT06716203
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT06716203. Randomized; double masking; primary purpose treatment. Start 2025-01-03 (actual); primary completion 2026-08-13 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise
- Condition
- Type 2 Diabetes Mellitus (T2DM)
- Intervention (Drug)
- Drug: 5 mg BGM0504 Administered SC
- Intervention (Drug)
- Drug: : 10 mg BGM0504 Administered SC
- Intervention (Drug)
- Drug: Placebo Administered SC
- Lead sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
- Collaborator
- BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd.
Record details
- Record id
cardio:ct-nct06716203- Content hash
ebc78cc4d86b48a36c4e997d09d82cb280c2eef598a815ab9bc94e0b0ff8941a